Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of GSK2340274A Influenza Vaccine in Healthy Japanese Adults
NCT00989612Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2009
- Primary completion
- Apr 2010
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant influenza ha vaccine (h5n1) in Influenza A H1N1 (H1N1), sponsored by GSK. Primary endpoints: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against A/California/7/2009 (H1N1)V-like Antigen at Day 42, Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies at Day 42 and 3 more. Started Oct 2009; status: completed.
02
Drugs
recombinant influenza ha vaccine (h5n1)
03
Conditions
Influenza A H1N1 (H1N1)
Beyond the preview
Go deeper on NCT00989612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00989612.